Keyur Monpara
About Keyur Monpara
Keyur Monpara is a Senior Manager in Global Regulatory Sciences at Bristol Myers Squibb and a Regulatory Affairs Change Lead at Norgine, with extensive experience in the pharmaceuticals and consulting industries.
Current Roles and Responsibilities
Keyur Monpara is currently serving as a Senior Manager in Global Regulatory Sciences at Bristol Myers Squibb. In addition, he holds the position of Regulatory Affairs Change Lead at Norgine in Harefield, Greater London, United Kingdom. His dual roles highlight his substantial expertise in regulatory sciences and regulatory affairs, addressing key compliance and regulatory challenges within the pharmaceuticals sector.
Previous Experience at Parexel
Keyur Monpara worked as a Senior Regulatory Associate at Parexel from 2019 to 2020. During his 8-month tenure in Uxbridge, Greater London, United Kingdom, he was involved in regulatory support and initiatives. This role contributed to his comprehensive experience in the field of regulatory affairs.
Roles at Medreich plc
At Medreich plc, Keyur Monpara held two significant positions. From 2016 to 2019, he served as Regulatory Affairs Officer in Feltham, Greater London, United Kingdom. Prior to this, he served as Senior Analytical Chemist from 2014 to 2016. Both roles allowed him to gain in-depth knowledge and experience in regulatory affairs and analytical chemistry within the pharmaceutical industry.
Early Career and Education
Keyur Monpara began his career as an Analyst at Zeta Analytical Ltd, working there from 2013 to 2014. He holds a Master’s Degree in Analytical Chemistry from Birkbeck, University of London, where he studied from 2009 to 2011. This educational background provided a strong foundation for his subsequent roles in pharmaceuticals and regulatory affairs.
Expertise and Skills
Keyur Monpara has expertise in Good Manufacturing Practice (GMP) and management within the pharmaceuticals and consulting industries. He is proficient in Microsoft Office and has strong social media skills. His extensive experience in regulatory affairs, garnered through his various roles since 2013, highlights his capability in addressing complex regulatory requirements in the pharmaceutical sector.